All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On 10 May 2018, a study was published in Haematologica assessing the use of rituximab and bendamustine in combination as front line therapy for frail elderly patients with diffuse large B-cell lymphoma (DLBCL). The paper was published by Sergio Storti, Universita Cattolica Sacro Cuore Campbasso, Italy, and colleagues from the Fondazione Italiana Linfomi (Italian Lymphoma Foundation).
The phase II study (NCT01990144) evaluated the efficacy and safety of the combination of bendamustine and rituximab in patients with previously untreated DLBCL. Patients were defined as ‘frail’ in-line with the Comprehensive Geriatric Assessment (CGA). The study addressed an unmet need in this patient population for the treatment of frail elderly patients who are unable to be treated with the standard R-CHOP therapy.
The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly frail patients with DLBCL. They noted that a larger sample size would be needed to further assess the PFS and OS in this treatment population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Bendamustine plus ofatumumab for naïve, elderly patients with DLBCL: Results from a phase II trial
This trial investigated the efficacy of bendamustine and ofatumumab in elderly patients with newly-diagnosed DLBCL, who were not good candidates for...
Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients
The results of this study ought to serve as a template and give rise to additional studies of novel induction regimens for elderly HL patients.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox